FDA reports shortage of Novo Nordisk’s weight loss drug Saxenda

Novo Nordisk is facing another shortage of one of its blockbuster drugs; this time it’s the weight loss drug liraglutide, better known as Saxenda.

According to the FDA’s drug shortage database, there will be limited availability of the 6 mg/ml version of Saxenda and the Saxenda pen through the end of the year. A Novo Nordisk spokesperson said that rising demand for weight management medicines has “put pressure on the supply” of Novo’s weight loss products, including Saxenda.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Two healthcare SPACs go public, with several more on the hunt for deals

The blank-check acquisition companies Launch One Acquisition and SIM Acquisition went public this week, a signal that the healthcare SPAC trend might not be totally

July 13, 2024

Transplant May Be Reasonable for Certain CRC Patients With Liver Mets

For a select group of patients with colorectal cancer and unresectable liver metastases, liver transplant may be a reasonable option, according to results from a

July 27, 2023

How Do You Select Systemic Therapy for Your Psoriasis Patients?

In this exclusive MedPage Today video, Richard Warren, MBChB, PhD, professor of Dermatology at the University of Manchester in England, explains how he approaches selecting

December 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.